Last reviewed · How we verify
A Randomized, Open-label, Multiple Dosing, Three-way Crossover Clinical Trial to Investigate the Pharmacokinetic Drug Interaction of LC15-0444 and Pioglitazone After Oral Administration in Healthy Male Subjects
The objective of the study is to investigate the drug interaction between LC15-0444 and pioglitazone by comparing the safety, tolerability and pharmacokinetics of LC15-0444 and pioglitazone are administered concomitantly and each alone in healthy male subjects.
Details
| Lead sponsor | LG Life Sciences |
|---|---|
| Phase | Phase 1 |
| Status | COMPLETED |
| Enrolment | 24 |
| Start date | 2009-02 |
| Completion | 2009-12 |
Conditions
- Healthy
Interventions
- LC15-0444, Pioglitazone
Primary outcomes
- AUCτ,ss, Cmax,ss of LC15-0444 and pioglitazone — During all dosing visits
Countries
South Korea